NEW YORK, NY, Nov. 4, 2013 /PRNewswire/ - Anavex Life Sciences Corp. ("Anavex"
or the "Company") (OTCQB: AVXL) announces that issue 38 (2013) of the
international scientific journal Neuropsychopharmacology contains a report demonstrating that ANAVEX 2-73 dose-dependently
blocks Tau and amyloid-beta ("amyloid") proteins and memory deficit in
a mouse model of Alzheimer's disease (AD). A reduction in these two
main hallmarks of Alzheimer's has the potential to stop, slow or
reverse the disease. The report also suggests that, because it is
targeting the mixed muscarinic and Sigma-1 receptors, ANAVEX 2-73 is
able to achieve its effect further "upstream" in the Alzheimer's
disease cascade. This compares to most other current AD clinical
development compounds that are mainly downstream and single-targeted
approaches, which might be limited by adverse effects. More
interestingly, the mixed muscarinic and Sigma-1 agonist ANAVEX 2-73
exhibited powerful effects despite its moderate affinity for these
receptors, emphasizing its great advantage for potential therapy in
Tangui Maurice, PhD, CNRS Research Director, Head of Team 2 'Endogenous
Neuroprotection in Neurodegenerative Diseases', at the University of
Montpellier and INSERM, and one of the study authors, said, "ANAVEX
2-73 also dose-dependently reduced C99 levels in the hippocampus, an
effect which researchers are currently trying to achieve with BACE
inhibitors. In the mouse model we also confirmed the central role of
the kinase GSK-3 beta in Alzheimer's disease toxicity through drugs
acting either directly as GSK-3 beta inhibitors, or indirectly, as
mixed muscarinic and Sigma-1 ligands. Both can efficiently alleviate
these two major alterations observed in the Alzheimer's animal model,
as well as in Alzheimer's patient brains. However, by targeting GSK-3
beta indirectly as ANAVEX 2-73 does through muscarinic and Sigma-1
ligands, we could avoid the toxicity seen by directly targeting GSK-3
Christopher U. Missling, PhD, President and Chief Executive Officer of
Anavex, said, "Using further upstream targets that efficiently block
tau phosphorylation and amyloid overproduction might be a more
comprehensive approach in successfully treating this complex disease.
Together with previously confirmed findings demonstrating the ability
of ANAVEX 2-73 to reduce mitochondrial oxidative stress, this
publication strengthens the case for a potential pharmacological
treatment for Alzheimer's disease."
The report, entitled "Blockade of Tau Hyperphosphorylation and
Amyloid-beta1-42 Generation by the Aminotetrahydrofuran Derivative ANAVEX 2-73, a Mixed
Muscarinic and Sigma-1 Receptor Agonist, in a Nontransgenic Mouse Model
of Alzheimer's Disease," is based on a scientific study conducted in
France at the University of Montpellier and INSERM.
The study was jointly conducted by Valentine Lahmy, Johann Meunier,
Susanna Malmstro, Gaelle Naert, Laurent Givalois, Seung Hyun Kim,
Vanessa Villard, Alexandre Vamvakides and Tangui Maurice. The full
paper is available on the Anavex website at http://anavex.com/publications.html.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a clinical stage biopharmaceutical company engaged in the
development of novel drug candidates to treat Alzheimer's, CNS diseases
and various types of cancer. ANAVEX 2-73, a drug candidate developed
to treat Alzheimer's through potential disease modification, has
undergone an initial Phase 1 human clinical trial and was well
tolerated in doses up to 55mg. Results from pre-clinical studies
indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective
properties. Anavex is a publicly traded corporation quoted as AVXL.
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the risks set forth in the Company's most
recent Annual Report on Form 10-K filed with the SEC. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Anavex Life Sciences Corp. undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof.
Anavex Life Sciences Corp.
Research & Business Development
Shareholder & Media Relations
Outside North America: +1 (416) 489-0092
SOURCE Anavex Life Sciences Corp.